Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Regulatory Update — Week of Dec. 25, 2023

  • Post author:PacConAdmin
  • Post published:December 29, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Over the past week, the FDA issued a final rule on direct-to-consumer prescription drug advertisements. The agency issued final guidance on development of drugs and biological products for rare diseases,…

Continue ReadingRegulatory Update — Week of Dec. 25, 2023

What’s Ahead for the FDA in 2024?

  • Post author:PacConAdmin
  • Post published:December 29, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA will kick off the new year under another possible threat of a shutdown because lawmakers have so far failed to agree on fiscal 2024 funding for the federal…

Continue ReadingWhat’s Ahead for the FDA in 2024?

J&J’s Acclarent Sees FDA Clearance as It Readies for Acquisition by Integra

  • Post author:PacConAdmin
  • Post published:December 28, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Acclarent, a division of Johnson & Johnson, has received FDA clearance for use of its AERA eustachian tube balloon dilation system in the treatment of children age 8-17 with persistent…

Continue ReadingJ&J’s Acclarent Sees FDA Clearance as It Readies for Acquisition by Integra

FDA, CISA Should Update Medical Device Cybersecurity Agreement, GAO Says

  • Post author:PacConAdmin
  • Post published:December 28, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

A five-year-old agreement between the FDA and the Cybersecurity and Infrastructure Security Agency (CISA) on medical device cybersecurity should be updated to reflect new practices, according to a recent report…

Continue ReadingFDA, CISA Should Update Medical Device Cybersecurity Agreement, GAO Says

Research Report – December 2023

  • Post author:PacConAdmin
  • Post published:December 28, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Research updates in this edition include drug successes for multiple myeloma, COPD, breast cancer and weight loss as well as disappointments in drugs for colorectal and endometrial cancer as well…

Continue ReadingResearch Report – December 2023

Amazon Gets Third FDA Warning Letter of 2023, Named in Five Others

  • Post author:PacConAdmin
  • Post published:December 28, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Amazon was hit with its third FDA warning letter of the year last week, this time for selling unapproved and incorrectly labeled products that contain the active ingredient in erectile…

Continue ReadingAmazon Gets Third FDA Warning Letter of 2023, Named in Five Others

FDA Guidances Clarify Testing for Benzene, Quality Considerations for Ophthalmic Drugs

  • Post author:PacConAdmin
  • Post published:December 27, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has issued a direct-to-final guidance on using benzene in drug manufacture and has revised a recently issued draft guidance on topical ophthalmic drug quality, an area in which…

Continue ReadingFDA Guidances Clarify Testing for Benzene, Quality Considerations for Ophthalmic Drugs

Coherus Bounces Back with Approval of Udenyca Onbody Post-Chemo Drug-Device

  • Post author:PacConAdmin
  • Post published:December 27, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Coming back from a complete response letter (CRL) for its Udenyca Onbody drug device combo, Coherus BioSciences has received FDA approval of the product to decrease the incidence of febrile…

Continue ReadingCoherus Bounces Back with Approval of Udenyca Onbody Post-Chemo Drug-Device

Quick Notes – Dec. 27, 2023

  • Post author:PacConAdmin
  • Post published:December 27, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

This edition of Quick Notes highlights drug approvals from regulators in the U.S. and Europe, while confirming December so far has been a pretty good month for Astellas Pharma with…

Continue ReadingQuick Notes – Dec. 27, 2023

In Bid to Keep Selling Watches, Apple Appeals Federal Import and Sales Ban

  • Post author:PacConAdmin
  • Post published:December 27, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Apple’s request earlier this week for an interim stay of federal orders to stop selling its watches is hardly an emergency, claims Masimo. Source: Drug Industry Daily

Continue ReadingIn Bid to Keep Selling Watches, Apple Appeals Federal Import and Sales Ban
  • Go to the previous page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.